Cargando…

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms

Detalles Bibliográficos
Autores principales:	Gleitz, Hélène F.E., Schneider, Rebekka K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153523/ https://www.ncbi.nlm.nih.gov/pubmed/36005565 http://dx.doi.org/10.3324/haematol.2022.281634

Ejemplares similares

Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2021)

Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis
por: Gleitz, Hélène FE, et al.
Publicado: (2018)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
por: Gjini, Evisa, et al.
Publicado: (2019)

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)

Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing
por: Gleitz, Hélène F.E., et al.
Publicado: (2021)

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
por: Molitor, David C. A., et al.
Publicado: (2020)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Fibrosis driving myofibroblast precursors in MPN and new therapeutic pathways
por: Gleitz, Hélène F.E., et al.
Publicado: (2019)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms
por: Vukotić, Milica, et al.
Publicado: (2022)

COP-eration for global food security
por: de la Barrera, Erick
Publicado: (2016)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report
por: Santaliestra, Marta, et al.
Publicado: (2020)

Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
por: Wen, Qiang Jeremy, et al.
Publicado: (2015)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017)

Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
por: Bonometti, Arturo, et al.
Publicado: (2022)

Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms
por: Moia, Riccardo, et al.
Publicado: (2021)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms
por: Schino, Mattia, et al.
Publicado: (2020)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm
por: Rahman, Mohammed Ferdous-Ur, et al.
Publicado: (2022)

Targeting Rho Associated Kinases in Leukemia and Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Crossing the Borders: An Integrated Approach to Myeloproliferative Neoplasms and Mastocytoses
por: Pizzi, Marco
Publicado: (2021)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
por: Koschmieder, Steffen, et al.
Publicado: (2018)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Leone, Aldo, et al.
Publicado: (2023)

Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms
por: Chen, Pu, et al.
Publicado: (2021)

Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons
por: Leiva, Orly, et al.
Publicado: (2023)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Arı, M. Cem, et al.
Publicado: (2012)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
por: Fleischman, Angela G.
Publicado: (2015)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qj17e9ghtkl2eqpcrp3ies3h1j